Aurinia Pharmaceuticals Inc
NASDAQ:AUPH

Watchlist Manager
Aurinia Pharmaceuticals Inc Logo
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Watchlist
Price: 8.86 USD 1.03% Market Closed
Market Cap: 1.3B USD
Have any thoughts about
Aurinia Pharmaceuticals Inc?
Write Note

Aurinia Pharmaceuticals Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Aurinia Pharmaceuticals Inc
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Operating Income
-$24.9m
CAGR 3-Years
46%
CAGR 5-Years
19%
CAGR 10-Years
-6%
B
Bright Minds Biosciences Inc
CNSX:DRUG
Operating Income
-CA$7.4m
CAGR 3-Years
-148%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Theratechnologies Inc
TSX:TH
Operating Income
$9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Repare Therapeutics Inc
NASDAQ:RPTX
Operating Income
-$116.2m
CAGR 3-Years
-30%
CAGR 5-Years
-55%
CAGR 10-Years
N/A
Covalon Technologies Ltd
XTSX:COV
Operating Income
-CA$1.4m
CAGR 3-Years
48%
CAGR 5-Years
23%
CAGR 10-Years
N/A
Spectral Medical Inc
TSX:EDT
Operating Income
-CA$14.1m
CAGR 3-Years
-20%
CAGR 5-Years
-38%
CAGR 10-Years
-2%
No Stocks Found

Aurinia Pharmaceuticals Inc
Glance View

Market Cap
1.3B USD
Industry
Biotechnology

Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases. The company is headquartered in Victoria, British Columbia and currently employs 300 full-time employees. The company went IPO on 2001-07-16. The firm is focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases. The firm has developed LUPKYNISTM, for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory advancement to support the voclosporin development program. LUPKYNIS is a calcineurin inhibitor (CNI) immunosuppressant, that improves near and long-term outcomes in LN when used in combination with mycophenolate mofetil and steroids. LUPKYNIS reduces cytokine activation and blocks interleukin IL-2 expression and T-cell mediated immune responses. Voclosporin, the active ingredient in LUPKYNIS, is made by a modification of a single amino acid of the cyclosporine molecule. The company also focuses on treatment of autoimmune, fibrotic, and kidney-related diseases. Its product pipeline includes AUR200, AUR300.

AUPH Intrinsic Value
12.02 USD
Undervaluation 26%
Intrinsic Value
Price

See Also

What is Aurinia Pharmaceuticals Inc's Operating Income?
Operating Income
-24.9m USD

Based on the financial report for Sep 30, 2024, Aurinia Pharmaceuticals Inc's Operating Income amounts to -24.9m USD.

What is Aurinia Pharmaceuticals Inc's Operating Income growth rate?
Operating Income CAGR 10Y
-6%

Over the last year, the Operating Income growth was 72%. The average annual Operating Income growth rates for Aurinia Pharmaceuticals Inc have been 46% over the past three years , 19% over the past five years , and -6% over the past ten years .

Back to Top